Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 4,248 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Alagille Syndrome
Interventions: Odevixibat, Placebo; Drug
Lead sponsor: Albireo; Industry
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Rabies in Animals, Worms; Intestine
Interventions: integrated delivery of deworming and vaccination, Mass deworming only, Mass vaccination of dogs; Other
Lead sponsor: Washington State University; Other
Eligibility: Not listed
Enrollment: 28,143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Narcolepsy
Interventions: SEP363856, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more

Conditions: Infantile Colic
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: The Archer-Daniels-Midland Company; Industry
Eligibility: 3 Weeks to 12 Weeks
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Endotoxin, Placebo; Biological · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Intracranial Meningioma
Interventions: [177Lu]Lu-DOTATATE, Standard of Care treatments; Drug · Other
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Irvine, California • La Jolla, California • New Haven, Connecticut + 14 more

Conditions: Tobacco Dependence
Interventions: C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening; Behavioral · Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Generalized Anxiety Disorder
Interventions: RE104 for Injection, Placebo; Drug
Lead sponsor: Reunion Neuroscience Inc; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more

Conditions: Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Interventions: LDGraft, Allograft Bone; Device · Other
Lead sponsor: Locate Bio Pty Ltd; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Fort Wayne, Indiana • Pinehurst, North Carolina • Nashville, Tennessee

Conditions: Malaria
Interventions: Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronavirus, Corona Virus Infection
Interventions: Group 1 HCQ, Group 2 Placebo; Drug
Lead sponsor: UnitedHealth Group; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Aging
Interventions: RHA® Redensity with new anesthetic agent, RHA® Redensity with lidocaine; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • New York, New York

Conditions: Organ Transplantation
Interventions: Belatacept, Sirolimus, Alemtuzumab; Drug
Lead sponsor: Allan D Kirk, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Caries, Erosive Tooth Wear
Interventions: 0 ppm fluoride toothpaste, 250 ppm fluoride toothpaste (dose-response control), 1150 ppm fluoride toothpaste, Mandibular intraoral appliance; Drug · Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Refractory Mixed Type Melasma
Interventions: Q-Switched Nd:YAG Laser (RevLite), Retin-A and microdermabrasion; Device · Drug
Lead sponsor: ConBio, a Cynosure Company; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocarditis Acute, Cancer
Interventions: Abatacept plus, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 29
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more

Conditions: Dental Caries
Interventions: C16G2 Varnish, Placebo Varnish; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Kalispell, Montana • Bedford, Texas • Irving, Texas

Conditions: Coronavirus Infection, Covid-19, SARS-CoV-2
Interventions: Ensifentrine Dose 1, Placebo pMDI; Drug
Lead sponsor: Verona Pharma Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoarthritis, Knee
Interventions: UBX0101, Placebo; Drug · Other
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more

Conditions: HIV, Adolescent Behavior, Gender
Interventions: Male-Specific Intervention Package, Female-Specific Intervention Package, Pre-Exposure Prophylaxis (Females), Cash Transfer Cohort (Females); Other · Drug · Behavioral
Lead sponsor: New York University; Other
Eligibility: 15 Years to 24 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Interventions: LHP588, Placebo Drug; Drug
Lead sponsor: Lighthouse Pharmaceuticals, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Murrieta, California + 34 more

Conditions: Breast Cancer, Tobacco Dependence
Interventions: placebo, varenicline; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurofibromatoses
Interventions: Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Integrating Community Interventions to Eliminate Neglected Tropical Diseases

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Contact: Developing New Clinical Management Strategies

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

C-Raven, a Virtual Tobacco Cessation Intervention in the Community

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)

Belatacept Post Depletional Repopulation to Facilitate Tolerance

New In Situ Model Design for Caries and Erosion

Study of Laser Treatment of Melasma

Abatacept in Immune Checkpoint Inhibitor Myocarditis

A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)